Phenformin Inhibits the Proliferation of MCF-7 and MDA-MB-231 Human Breast Cancer Cell Lines
- 15 January 2023
- journal article
- research article
- Published by LookUs Bilisim A.S. in Medical Records
- Vol. 5 (1) , 103-6
Abstract
Aim: Breast cancer is the most common malignancy in women. This disease is a critical public health problem and further research at the molecular level would define its prognosis and specific treatment. Phenformin is an antidiabetic agent. Recent studies showed that it should be considered as a potential agent for the prevention and treatment of cancer cell lines. This study aimed to investigate the antiproliferative effect of phenformin on MDA-MB-231 and MCF-7 breast cancer cell lines. Materials and Methods: MDA-MB-231 and MCF-7 breast cancer cell lines were used in the study. Experimental groups; control group, 1 µM, 2.5 µM, and 5 µM phenformin administered groups were planned. WST-1 analysis was performed to evaluate the viability of cells 24 h after the treatments. Statistical analysis was carried out using the SPSS 17.0 statistical program. p<0.05 was considered to indicate a statistically significant difference.Results: In the MDA-MB-231 breast cancer cell line, there were statistically significant differences among all groups (p0.05). In the MCF-7 breast cancer cell line; there were statistically significant differences between the control group and 5 µM phenformin-treated, and between 1 µM phenformin-treated and 5 µM phenformin-treated (p<0.05, for all) groups. Conclusion: Phenformin seems to exert antiproliferative effects on MDA-MB-231 and MCF-7 breast cancer cell lines. It was observed that the antiproliferative effect was stronger in the MDA-MB-231 cell line. It showed a stronger antiproliferative effect in the MDA-MB-231 cell line of antiproliferative effect.Keywords
This publication has 13 references indexed in Scilit:
- The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytesOncotarget, 2019
- Psychosocial Adaptation During and After Breast Cancer2019
- Phenformin inhibits growth and epithelial-mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathwayOncotarget, 2017
- Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant MelanomaJournal of Investigative Dermatology, 2017
- miR-27a-mediated antiproliferative effects of metformin on the breast cancer cell line MCF-7Oncology Reports, 2016
- Hinokitiol inhibits vasculogenic mimicry activity of breast cancer stem/progenitor cells through proteasome-mediated degradation of epidermal growth factor receptorOncology Letters, 2016
- Phenformin Induces Cell Cycle Change, Apoptosis, and Mesenchymal-Epithelial Transition and Regulates the AMPK/mTOR/p70s6k and MAPK/ERK Pathways in Breast Cancer CellsPLOS ONE, 2015
- Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cellsProceedings of the National Academy of Sciences, 2014
- Synergistic Anti-Cancer Effect of Phenformin and OxamatePLOS ONE, 2014
- Phenformin as prophylaxis and therapy in breast cancer xenograftsBritish Journal of Cancer, 2012